Concepedia

Biological characteristics and treatment outcomes of metastatic or recurrent neuroendocrine tumors: tumor grade and metastatic site are important for treatment strategy

Su‐Jung Kim, Jin Won Kim, Sae‐Won Han, Do‐Youn Oh, Se‐Hoon Lee, Dong‐Wan Kim, Seock‐Ah Im, Tae‐You Kim, Dae Seog Heo, Yung‐Jue Bang

BMC Cancer · 2010 · 49 citations · 25 references

DOIFull text

Open access

References

25

Placebo-Controlled, Double-Blind, Prospective, Randomized Study on the Effect of Octreotide LAR in the Control of Tumor Growth in Patients With Metastatic Neuroendocrine Midgut Tumors: A Report From the PROMID Study Group

Anja Rinke, Hans‐Helge Müller, Carmen Schade‐Brittinger et al. · Journal of Clinical Oncology · 2009 · 2.5K citations

Treatment With the Radiolabeled Somatostatin Analog [ <sup>177</sup> Lu-DOTA <sup>0</sup> ,Tyr <sup>3</sup> ]Octreotate: Toxicity, Efficacy, and Survival

Dik J. Kwekkeboom, Wouter W. de Herder, Boen L.R. Kam et al. · Journal of Clinical Oncology · 2008 · 1.4K citations · Full text

Streptozocin–Doxorubicin, Streptozocin–Fluorouracil, or Chlorozotocin in the Treatment of Advanced Islet-Cell Carcinoma

Charles G. Moertel, Myrto Lefkopoulo, Stuart R. Lipsitz et al. · New England Journal of Medicine · 1992 · 969 citations · Full text

Treatment of neuroendocrine carcinomas with combined etoposide and cisplatin. Evidence of major therapeutic activity in the anaplastic variants of these neoplasms

Charles G. Moertel, Larry K. Kvols, Michael J. O’Connell et al. · Cancer · 1991 · 839 citations · Full text

, , +13

Streptozocin Alone Compared with Streptozocin plus Fluorouracil in the Treatment of Advanced Islet-Cell Carcinoma

Charles G. Moertel, James A. Hanley, Lewis A. Johnson · New England Journal of Medicine · 1980 · 651 citations